'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models (2021) Hayer S, Vervoordeldonk MJ, Denis MC, Armaka M, Hoffmann M, Bäcklund J, Nandakumar KS, et al. Journal article EULAR definition of difficult-To-Treat rheumatoid arthritis (2021) Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, Van Der Goes MC, Kent A, et al. Journal article Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging (2020) Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Götz TI, Soare A, Cordes M, et al. Journal article Digital crowdsourcing: Unleashing its power in rheumatology (2020) Krusche M, Burmester GR, Knitza J Journal article, Review article PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis (2020) Zhang Y, Shen L, Zhu H, Dreissigacker K, Distler D, Zhou X, Györfi AH, et al. Journal article DOES ANTI-ACID TREATMENT INFLUENCE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD)? DATA FROM THE GERMAN SSC-NETWORK (2020) Kreuter M, Bonella F, Riemekasten G, Mueller-Ladner U, Henes J, Siegert E, Guenther C, et al. Conference contribution CONTRIBUTION OF DEFECTIVE NON-APOPTOTIC FAS SIGNALING TO IMMUNE DYSREGULATION IN AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) (2020) Staniek J, Kalina T, Andrieux G, Boerries M, Janowska I, Fuentes M, Bakardjieva M, et al. Conference contribution TIME TO FLARE AND GLUCOCORTICOID EXPOSURE IN PATIENTS WITH NEW-ONSET VERSUS RELAPSING GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB OR PLACEBO PLUS PREDNISONE TAPERING: 3-YEAR RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3 TRIAL (2020) Stone JH, Spotswood H, Unizony S, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES (2020) Mcgonagle D, Mcinnes I, Deodhar A, Schett G, Mease PJ, Shawi M, Kafka S, et al. Conference contribution NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL (2020) Volkmann E, Castellvi I, Johnson S, Matteson E, Distler J, Seibold J, Costabel U, et al. Conference contribution